

CB SCIENTIFIC, INC.

Entry into Material Definitive Agreement

CB Scientific, Inc. Announces Collaborative Partnership Agreement with Shenzhen Semacare Medical Technology Co., Ltd.

February 10, 2021

(Date of Report)

CB SCIENTIFIC, INC.

(Exact Name of Registrant as Specified in its Charter)

340 State Place, Escondido, CA 92029

(Address of principle executive offices)

888-225-0870

(Registrant's telephone number, including area code)

CB Scientific, Inc. (CBSC)

CB Scientific, Inc. Announces Collaborative Partnership Agreement with Shenzhen Semacare Medical Technology Co., Ltd.

CB Scientific, Inc. (CBSC), in its ongoing efforts to expand its products and services in the Remote Cardiac Ambulatory ECG market, both domestically and internationally, is pleased to announce that it has entered into a collaborative partnership agreement (CPA) with Shenzhen Semacare Medical Technology Co., Ltd. (Semacare), a privately held medical technology company based in Shenzhen, Guangdong, China. Semacare brings their MetaCor real-time remote monitoring device, which has been certified and approved in China by the National Medical Products Administration (“NMPA”), and their associated wireless, waterproof patch electrode, including their MetaAI innovative artificial intelligence machine learning algorithm to CBSC. This partnership will help to further strengthen and diversify both companies by improving CBSC’s existing and future digital products and features, while helping to expand the outreach of Semacare’s MetaCor product offering, internationally.

Under the terms of the CPA, the two companies will provide mutual assistance in pursuing regulatory approvals for their individual products. CBSC will endeavor to consult and assist Semacare in their efforts towards regulatory approval of the MetaCor monitoring device for CE and US FDA 510(k) registration. Semacare will assist CBSC in the current regulatory approval process with the NMPA in China for its my-Cam monitoring device. During the term of this agreement, mutual efforts will be made towards the joint development of products, including interoperability between Semacare monitoring products and CB Scientific’s current and future monitoring solutions. This includes assistance by Semacare to help develop a wireless, waterproof patch solution for CBSC devices. As part of this agreement our two companies will explore a broad scope of joint collaborations and relationships to include the possibility of a future strategic business combination, merger or acquisition.

Company Contact Information:

Address:

340 State Place
Escondido, CA 92029

Telephone number:

(888) 225-0870

Emails:

General inquires: info@cbscientificinc.com

Investor Inquiries: investor@cbscientificinc.com

Social Media Outlets:

Twitter, Facebook, Instagram, and LinkedIn

CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings, as new developments occur.

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SIGNATURES

The Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 10, 2021

CB SCIENTIFIC, INC.

By: /s/ Charles Martin

Charles Martin,
President